PC4 1.2.2 Only molecules

2-[(2-pyridinyl)methylsulfinyl]-1H-benzimidazole

False, only a few changes are tolerated

What is the MOA

MOA of PPIs: they are prodrugs that get activated by stomach acid

Mechanism based inhibitor

What is this structure O-methyls on ends

Omeprazole

What is this structure. 3 fluorines attached to O substituents on benzimidizole

Lansoprazole

What is this? 2F attached to O substituent on pyridine PLUS 2 O substituents on benzimidizole

Pantoprazole

What is this? Long substituent on benzimidizole

Rabeprazole

CYP2C19: O-demethylation

CYP3A4: Sulfoxidation

CYP2C19: hydroxylation demethylation

C: Pantoprazole

B: Lansoprazole

D: Rabeprazole

S atom

The R-enantiomer would be expected to decrease the inter individual variability

S-enantiomer has less bioavailability variations than the R enantiomer among the slow metabolizers

A: N is missing, necessary for prodrug to activate in acidic environment

What is this structure

Misoprostol

G-protein coupled receptor-mediated inhibition of adenylate cyclase, which leads to levels decreased intracellular cyclic AMP and decreased proton pump activity apical surface of the parietal cell

For use by people who are both taking NSAIDs and are at high risk for NSAID induced ulcers .

What is this

Bismuth Subsalicylate (antiacid)

Sucralfate (antacid)